Serum TNF-Related and Weak Inducer of Apoptosis Levels in Septic Shock Patients

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 4, 2011, Pages 342-348

  Nagai, Miho ^a   Hirayama, Kouichi ^a   Ebihara, Itaru ^b   Higuchi, Takashi ^a   Imaizumi, Masahiro ^a   Maruyama, Hiroshi ^a   Miyamoto, Yasunori ^a   Kakita, Tomoko ^c   Ogawa, Yujiro ^a   Fujita, Shogo ^a   Shimohata, Homare ^a   Kobayashi, Masaki ^a  

^a Tokyo Medical University Ibaraki Medical Center   (Japan)

^b MITO SAISEIKAI GENERAL HOSPITAL   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Capillary permeability; Direct hemoperfusion with polymyxin B immobilized fiber column; Sepsis; TNF related and weak inducer of apoptosis

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; C REACTIVE PROTEIN; POLYMYXIN B IMMOBILIZED FIBER COLUMN; POLYMYXIN DERIVATIVE; TORAYMYXIN PMX; TUMOR NECROSIS FACTOR DERIVATIVE; TUMOR NECROSIS FACTOR RELATED AND WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CAPILLARY PERMEABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPERFUSION; HUMAN; INFLAMMATION; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN IMMOBILIZATION; SEPTIC SHOCK; SURVIVOR; THROMBOCYTE COUNT;

AGED; AGED, 80 AND OVER; ANGIOPOIETIN-1; ANGIOPOIETIN-2; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAPILLARY PERMEABILITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOPERFUSION; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; POLYMYXIN B; SEVERITY OF ILLNESS INDEX; SHOCK, SEPTIC; SURVIVORS; TUMOR NECROSIS FACTORS;

EID: 80051961507     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00966.x     Document Type: Article

References (27)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
2. Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996;154:617-24.
3. Tani T, Hanasawa K, Endo Y etal. Therapeutic apheresis for septic patients with organ dysfunction: hemoperfusion using a polymyxin B immobilized column. Artif Organs 1998;22:1038-44.
4. Ebihara I, Hirayama K, Kaneko S etal. Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with polymyxin B-immobilized fiber. Ther Apher Dial 2008;12:285-91.
5. Ebihara I, Hirayama K, Nagai K etal. Angiopoietin balance in septic shock patients treated with direct hemoperfusion with polymyxin B-immobilized fiber. Ther Apher Dial 2009;13:520-7.
6. van Meurs M, Kümpers P, Ligtenberg JJM, Meertens JHJM, Molema G, Zijlstra JG. Bench-to-bedside review: angiopoietin signalling in critical illness-a future target? Crit Care 2009;13:207.
7. Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis 2008;11:109-19.
8. Chicheportiche Y, Bourdon PR, Xu H etal. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-10.
9. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 2007;40:1-16.
10. Bone RC, Balk RA, Cerra FB etal. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
11. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981;9:591-7.
12. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-9.
13. Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H. Involvement of TWEAK in interferon γ-stimulated monocyte cytotoxicity. J Exp Med 2000;192:1373-9.
14. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002;299:488-93.
15. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappa B activation. J Biol Chem 2003;278:36005-12.
16. Chacón MR, Richart C, Gómez JM etal. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine 2006;33:129-37.
17. Xu H, Okamoto A, Ichikawa J etal. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004;318:422-7.
18. Campbell S, Burkly LC, Gao HX etal. Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J Immunol 2006;176:1889-98.
19. Maecker H, Varfolomeev E, Kischkel F etal. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005;123:931-44.
20. Kawamata T, Imaizumi H, Yoshida M, Kaneko M. Polymyxin B-immobilized fiber improves hyperdynamic state in MRSA septic patients. Intensive Care Med 1997;23:130-1.
21. Jaber BL, Barrett TW, Neto MC, Sundaram S, King AJ, Pereira BJG. Removal of cytokine inducing substances by polymyxin-B immobilized polystyrene-derivative fibers during in vitro hemoperfusion of 10% human plasma containing Staphylococcus aureus challenge. ASAIO J 1998;44:48-53.
22. Grootendorst AF. The potential role of hemofiltration in the treatment of patients with septic shock and multiple organ dysfunction syndrome. Adv Renal Replace Ther 1994;1:176-84.
23. De Vriese AS, Colardyn FA, Philippé JJ, Vanholder RC, De Sutter JH, Lameire NH. Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-53.
24. Marsters SA, Sheridan JP, Pitti RM, Brush J, Goddard A, Ashekenazi A. Identification of a ligand for the death domain containing receptor Apo3. Curr Biol 1998;8:525-8.
25. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-9.
26. Donohue PJ, Richards CM, Brown SA etal. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594-600.
27. Orfanos SE, Kotanidou A, Glynos C etal. Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators. Crit Care Med 2007;35:199-206.